drug

RO6889450

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Hoffmann-La Roche
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
NCT03669640Phase 2Terminated
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
NCT04512066Phase 2Completed

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Hoffmann-La Roche
company
trial
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
PHASE2
trial
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia, Schizoaffective Disorder
indication
Psychotic Disorders
indication